Autolus Therapeutics (AUTL) announced that the National Institute for Health and Care Excellence has published draft guidance recommending Aucatzyl for use in the National Health Service in England and Wales as a treatment option for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Aucatzyl will be available through routine commissioning by the NHS. Autolus intends to launch Aucatzyl in England and Wales imminently. Autolus also intends to pursue patient access to Aucatzyl through the Scottish Medical Consortium.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Autolus Therapeutics Reports Q3 2025 Financial Results
- Autolus Therapeutics’ Earnings Call: Mixed Sentiments
- Autolus Therapeutics: Strong Buy Rating Backed by Growth Potential and Strategic Advancements
- Autolus Therapeutics: Promising Growth and Market Expansion Justify Buy Rating
- Midday Fly By: AMD sees acceleration, IBM unveils quantum processor